Video Programs

Learn how zangontinib affects atorvastatin, raises liver-risk, and why frequent LFTs plus entecavir may prevent hepatitis B reactivation.

EGFR lung cancer trials show combo therapy better prevents brain metastases, improving intracranial response and PFS compared with osimertinib alone.

Dr. Doroshow addresses financial toxicity as a central concern in Sandra's case and broader challenge in HER2-directed therapy access. Sandra has high-deductible Affordable Care Act marketplace plan with $6,000 annual deductible, is currently on medical leave with uncertain prospects for returning to work and is understandably worried about out-of-pocket expenses that reset each calendar year.

New trial data weigh EGFR lung cancer first-line combos, hinting amivantamab–lazertinib may edge osimertinib plus chemo, especially with TP53.

This episode examines Dr. Doroshow's approach to safety counseling when selecting among HER2-directed therapies, with particular attention to Sandra's concern about interstitial lung disease risk given prior pembrolizumab exposure.

Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects including immune effector cell-associated neurotoxicity syndrome (ICANS), which can manifest as weakness and create diagnostic overlap concerns with cancer-associated LEMS symptoms.

Dr. Leal addresses the complex interaction between cancer-associated LEMS as an autoimmune condition and standard SCLC therapies, particularly immunotherapy agents like checkpoint inhibitors and newer treatments like tarlatamab T-cell engagers.

Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at neuromuscular junctions for treating LEMS, including cancer-associated cases.

In this closing segment on advanced renal cell carcinoma, Dr. Wulff invites final reflections on anticipated changes in treatment guidelines over the coming year.

In this segment on advanced renal cell carcinoma, Dr. Geynisman focuses on key principles for applying NCCN guideline recommendations in real-world community practice.

New data show zongertinib is well tolerated in frontline lung cancer, with manageable diarrhea, minimal rash, and low ILD risk.

Dr. Leal discusses the updated NCCN guidelines recommending VGCC antibody testing for patients with suspected neurologic paraneoplastic syndromes like cancer-associated LEMS, asking about the impact of these guideline changes on awareness and testing rates in community and academic settings. Dr. Iams acknowledges the guidelines help somewhat but emphasizes that broader awareness of the diagnosis and specific available treatments remain more significant factors in improving recognition.

Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with small-cell lung cancer (SCLC). This paraneoplastic syndrome affects approximately 3% of patients with SCLC but remains undiagnosed in up to 90% of cases, representing a significant clinical challenge where symptoms often overlap with expected disease progression or treatment-related adverse effects in busy oncology settings.

NCCN guidance highlights how HER2-mutant lung cancer may still benefit from chemo‑immunotherapy, as PD‑L1 and response patterns differ from EGFR/ALK/RET/ROS1.

Trial data guide EGFR lung cancer first-line choices: amivantamab+lazertinib may edge osimertinib+chemo, especially with TP53 mutations.

This episode focuses on practical decision-making for selecting among HER2-directed therapies after progression on chemo-immunotherapy.

Compare EGFR lung cancer first-line options—osimertinib, amivantamab/lazertinib, or chemo combo—balancing visits, survival, and risks.

This episode examines second-line therapy selection when brain metastases are present in HER2-mutant non-small cell lung cancer.

Zongertinib shows 77% frontline responses and 96% disease control, with rapid onset and promising durability versus other HER2 TKIs.

In this segment on advanced renal cell carcinoma, Dr. McGregor highlights the challenges of managing comorbidities in community practice and how these factors influence treatment selection. Dr. Wulff and Dr. Geynisman discuss practical strategies for adapting guideline-based therapies in patients with cardiovascular disease, pulmonary conditions, and baseline anemia.

In this segment on advanced renal cell carcinoma, Dr. Geynisman discusses how clinicians decide between single-agent TKIs and combination approaches in later-line treatment settings.

FDA‑approved zongertinib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.

Limited lung cancer tissue? Pair liquid biopsy with NGS to spot actionable mutations fast and choose targeted therapy without delaying care.

Explore first-line therapy for HER2-mutated advanced NSCLC in an older patient, covering biomarker testing, liquid biopsy timing, and tailored HER2-targeted options.

Dr. Doroshow addresses the critical gap that shaped Sandra's treatment trajectory: incomplete upfront molecular testing in community oncology.

Dr. Gumbleton frames the three preferred front-line options for EGFR-driven NSCLC: osimertinib monotherapy, amivantamab plus lazertinib, and osimertinib plus chemotherapy against Mrs. Chen's stated goals of maximizing long-term survival, minimizing clinic visits, and staying chemo-free if possible.

Dr. Matthew Gumbleton introduces the case of Mrs. Chen, a 58-year-old Asian woman and never-smoker who presents with progressive shortness of breath and about 10 pounds of unintentional weight loss over 2 months.

Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung cancer (NSCLC), adenocarcinoma subtype.